Otsuka Pharmaceutical Co., Ltd.
August 8, 2011
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' is Covered under Japanese Insurance Program, effective as of August.
Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that its WT1 mRNA Assay KitO 'tsuka', an in-vitro diagnostic kit by the quantitative real time RT-PCR method is now covered under the Japanese national health insurance program, effective on August 1, 2011, for Myelodysplastic Syndromes (MDS) in addition to Acute Myeloid Leukemia (AML).
Information in this news release was current as of the original release date.